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OPA1 Mutation and Late-Onset Cardiomyopathy: Mitochondrial
Dysfunction and mtDNA Instability
Le Chen, MD, PhD; Tingting Liu, BS; Alice Tran, BS; Xiyuan Lu, MS; Alexey A. Tomilov, PhD; Vanessa Davies, PhD; Gino Cortopassi, PhD;
Nipavan Chiamvimonvat, MD; Donald M. Bers, PhD; Marcela Votruba, MD, PhD, FRCOphth; Anne A. Knowlton, MD
Background-—Mitochondrial fusion protein mutations are a cause of inherited neuropathies such as Charcot–Marie–Tooth disease
and dominant optic atrophy. Previously we reported that the fusion protein optic atrophy 1 (OPA1) is decreased in heart failure.
Methods and Results-—We investigated cardiac function, mitochondrial function, and mtDNA stability in a mouse model of the
disease with OPA1 mutation. The homozygous mutation is embryonic lethal. Heterozygous OPA+/ mice exhibit reduced mtDNA
copy number and decreased expression of nuclear antioxidant genes at 3 to 4 months. Although initial cardiac function was
normal, at 12 months the OPA1+/ mouse hearts had decreased fractional shortening, cardiac output, and myocyte contraction.
This coincided with the onset of blindness. In addition to small fragmented mitochondria, aged OPA1+/ mice had impaired cardiac
mitochondrial function compared with wild-type littermates.
Conclusions-—OPA1 mutation leads to deﬁciency in antioxidant transcripts, increased reactive oxygen species, mitochondrial
dysfunction, and late-onset cardiomyopathy. ( J Am Heart Assoc. 2012;1:e003012 doi: 10.1161/JAHA.112.003012)
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M itochondria were long viewed as vital but static energyfactories; however, mitochondria have been found to
be dynamic organelles that not only continuously divide and
fuse within the cell, but also have functions extending beyond
energy production to cell signaling.1,2 Complete mitochondrial
fusion requires 2 steps, in which the outer and inner
mitochondrial membranes fuse in separate events.2 The
mitofusins MFN1 and MFN2 are on the mitochondrial outer
membrane and are involved in the ﬁrst step of mitochondrial
fusion, whereas optic atrophy 1 (OPA1) fuses the inner
membrane. On the other hand, mitochondrial ﬁssion is
controlled by Fis1 and DRP1 in mammalian cells. The rate
of ﬁssion and fusion in mammalian cells is thought to be much
slower than that in simpler organisms such as yeast, in which
fusion and ﬁssion were ﬁrst described.3
Recent studies have explored whether maintaining overall
mitochondrial morphology and function relies on preserving
the balance of fusion and ﬁssion. Imbalanced mitochondrial
fusion/ﬁssion leads to apoptosis, mitochondrial DNA (mtDNA)
mutations, and a severe reduction in respiratory capacity.1,4
There are a number of inherited neuropathies such as
Charcot–Marie–Tooth disease and dominant optic atrophy
that cause neuropathy and blindness. Several of these
diseases have been shown to be caused by mutation of
MFN25 and OPA1.6,7 Abnormal expression of MFN2 has also
been found in other diseases including Parkinson’s disease
and type 2 diabetes.1
The heart, like the brain, has a high demand for ATP and is
dependent on mitochondrial high-energy phosphate produc-
tion. However, only limited studies have addressed whether
mitochondrial fusion/ﬁssion abnormalities have a role in
heart failure. We have previously reported that OPA18 is
decreased in both human and rat heart failure. Electron
microscopic analysis showed increased number and
decreased size of mitochondria, consistent with depressed
mitochondrial fusion, in a high coronary artery ligation rat
heart failure model. However, it remains unknown whether
this reduction of mitochondrial fusion is secondary to heart
failure or a contributor to the development and progression of
heart failure. Investigation has been limited on the role of
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OPA1-mediated mitochondrial fusion in the heart. There also
remain concerns whether mitochondrial dynamic changes
occur readily in cardiac muscle ﬁbers, where mitochondria are
highly organized and compacted between contractile ﬁla-
ments or adjacent to the sarcolemma. However, given the
heart’s high energy requirements, it seems very likely that
changes in fusion proteins would have a negative impact on
cardiac function.
To address our hypothesis that loss of fusion proteins
contributes to the development of cardiomyopathy, we
studied mice with an OPA1 mutation, modeling dominant
optic atrophy. We found that these mice had a late onset of
cardiomyopathy. Furthermore, reduction in OPA1 led to
abnormalities in mitochondrial organization, depressed mito-
chondrial respiration, and increased mtDNA deletion, as well
as increased reactive oxygen species (ROS).
Experimental Procedures
Mouse Breeding
OPA1 mutation has been generated as previously described;
the introduced stop codon is at the beginning of the dynamin
GTPase, a domain where many human disease-causing
mutations cluster.9 OPA1+/ mice and littermate controls
were bred by crossing OPA1+/ and WT C57Bl/6JCrl
(Charles River). This has been continuing from G2 to G16
(currently). Animals aged 3 to 4 months (3 months) and 12
to 14 months (12 months) were used. All experiments were
approved by the Institutional Animal Care and Use Commit-
tee at UC Davis.
Cardiac Functional Measurements
Echocardiography
In all, 6 to 7 age- and sex-matched WT and OPA1+/ mice
were examined at different ages (monthly). Murine transtho-
racic echocardiography was conducted in conscious mice
as previously described.10 Brieﬂy, the heart was imaged in a
2-dimensional parasternal short-axis view with M-mode
echocardiogram of the midventricle recorded at the level of
the papillary muscle. Left ventricle (LV) fractional shortening
was calculated as previously described.10
Hemodynamics measurements
Hemodynamics measurements were performed as previously
described.11 Brieﬂy, a lateral thoracotomy was done, and a
2.0 f Millar catheter was passed through the left carotid
artery into the left ventricular chamber. Hemodynamic
function was measured, including volume loops and cardiac
output.
Cardiomyocyte contractility and calcium transients
Cardiomyocyte contractility and calcium transients were
synchronously detected using an IonOptix system (IonOptix,
Milton, MA) as previously described.12
Histological and Electron Microscopy Analysis
The left ventricle was used for histological analysis. COX/
SDH staining was performed according to the method of
Chen et al.13 Freshly dissected heart tissue was embedded in
Optimal Cutting Temperature (OCT) compound (Tissue-Tek)
and frozen in liquid nitrogen. Slides were stained for COX
activity, washed in water, stained for SDH activity, washed,
and mounted in GelMount (Biomeda). For electron micros-
copy (EM), mouse hearts were ﬁxed with 4% paraformalde-
hyde and then processed and imaged as described
previously.8
Respiration Measurements
Oxygen consumption was measured in freshly isolated cardiac
mitochondria using the XF24 Seahorse instrument, modiﬁed
based on a previously described method.14 State II respiration
was initiated by adding substrate— 5 mmol/L succinate in the
presence of 2 lmol/L rotenone. State III respiration was
measured by the addition of ADP to a ﬁnal concentration of 2.5
mmol/L. Uncoupled respiration rates were determined by injec-
tion of 2.5 lmol/L mesoxalonitrile 4-triﬂuoromethoxyphenylhyd-
razone (FCCP). State IV respiration was measured following ADP
consumption. Respiration due to proton leak was determined
using 0.5 lmol/L oligomycin.
Complex I, II, and IV activities were measured in freshly
isolated mitochondrial lysates following the recommendations
of the manufacturer (Mitoscience) as previously reported.15
ATP Production Rates in Isolated Heart
Mitochondria
ATP synthesis rates in isolated heart mitochondria were
determined using the luciferin/luciferase-based ATP Biolumi-
nescence Assay Kit (Sigma) essentially as described.16 Basal
ATP content in heart left ventricle tissue was directly
measured using tissue lysate. For complex I-driven ATP
synthesis, 5 to 10 lg of heart mitochondria was dissolved in
50 lL of buffer A (125 KCL, 10 mmol/L HEPES, 5 mmol/L
MgCl2, and 2 mmol/L K2HPO4, pH 7.44) plus complex I
substrate pyruvate/malate, 5 mmol/L ﬁnal, with and without
2 mmol/L rotenone. The ATP measurements in the presence
of rotenone were subtracted to give ATP production via
complex I. The measurements for all samples were started
simultaneously by adding 50 lL of luciferin/luciferase buffer
containing 1 mmol/L ADP (0.5 mmol/L ﬁnal). Using an ATP
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standard provided in the kit, the slopes were converted to
nanomoles per minute per milligram of protein.
DNA Isolation
To isolate mtDNA, mouse left ventricles were ﬁrst homoge-
nized, and a mitochondrial fraction was isolated according to
previously published protocols.13 Mitochondria were then
lysed in the presence of 0.5% SDS and 0.2 mg/mL proteinase
K in 10 mmol/L Tris-HCl, 0.15 mol/L NaCl, and 0.005 mol/L
EDTA. mtDNA was then extracted and puriﬁed with Dynabeads
(Invitrogen). Total DNA was isolated using standard protocols.
mtDNA Quantitation
To quantify the amount of mtDNA present per nuclear
genome, we used the primers as listed in Table S3. All
samples were measured in triplicate, and qPCR results
obtained were conﬁrmed by 3 independent experiments.
Two different primer pairs were used to quantify and conﬁrm
relative mtDNA copy number as previously described14: COXI
and cytochrome b (mitochondrial) and b-globin/H-19 for
genomic DNA. Data obtained by qPCR were analyzed by the
DDCT method.
Apoptosis Assays
TUNEL staining was performed on heart sections using a
commercial kit (In Situ Cell Death Detection Kit, Roche)
following the manufacturer’s instructions. Percentage of
TUNEL positive cells was calculated as previously described.8
Western Blotting
The left ventricle was homogenized in RIPA buffer as
previously described,8 Fifty micrograms of lysate was elec-
trophoresed and transferred to nitrocellulose membranes.
Blots were blocked with 5% nonfat dry milk and incubated
overnight at 4°C with anti-TFAM, PGC1-a, MFN1, MFN2, Bax,
Bak, and Nrf2 antibodies (Abcam, 1:1000); GAPDH was used
as an internal control. Blots then were washed and incubated
with secondary antibodies (1/10 000 goat anti-rabbit-HRP/
anti-mouse-HRP, GE) and developed with the Femto chemi-
luminescent reagent (Pierce).
ROS Assays
ROS level was measured by a ﬂuorescent method with
confocal microscopy. CellROX deep red (Invitrogen) was used
as indicator of cell ROS. Cardiomyocytes were isolated as
previously described,16 and myocytes were incubated with
CellROX at 37°C for 30 minutes. Nuclei indicator DAPI was
used as a counterstain. The intensity of CellROX ﬂuorescence
was calculated and analyzed to quantify the ROS level. One
hour of hypoxia followed by 1 hour of reoxygenation was
performed using standard protocols as previously described.8
Total antioxidant capacity (TAC) was measured using a TAC
ELISA kit (Cell Biolabs) following the manufacturer’s protocol.
Brieﬂy, left ventricles were homogenized and centrifuged at
10 000g for 10 minutes at 4°C. One hundred milligrams of
supernatant was loaded into a 96-well plate for subsequent
TAC assay. After 30 minutes’ incubation with copper
ion reagent, the reduction of copper(II) to copper(I) by anti-
oxidants was measured for absorbance at 490 nm.
PCR Array
Total RNA was extracted from mouse left ventricle by the
standard Trizol (Invitrogen) method, and PCR array was
performed following the manufacturer’s protocol. Mitochon-
drial gene and stress-related gene PCR arrays (Qiagen) were
used to determine the gene proﬁle changes in OPA1-mutant
hearts. Data obtained by qPCR were analyzed by the DDCT
method.
Statistical Analysis
Results are expressed as mean±SEM. Results from multiple
groups were compared by analysis of variance (ANOVA)
followed by a Student–Neuman–Keuls test for multiple
comparisons. The Student t test was used for comparisons
involving only 2 groups. The Wilcoxon rank-sum test and
Krusakl–Wallis ANOVA were performed when data were not
normally distributed. A P<0.05 was considered signiﬁcant. In
PCR array analysis, q value was calculated using Q-Value
software (http://genomics.princeton.edu/storeylab/qvalue/).
A limitation of the study was the relatively small sample size
for some experiments.
Results
Abnormal Cardiac Function in OPA1 Mutants
at 12 Months
An OPA1 gene mutation, B6;C3-Opa1(Q285STOP), which
models autosomal dominant optic atrophy, was generated in
the mouse.9 The homozygous mutation is embryonic lethal,
whereas the heterozygous mutation is associated with visual
dysfunction and structural changes in the murine retina and
optic nerve beginning at 12 months.9 The animals looked
vigorous and appeared healthy. Initial descriptive studies of
the heart showed no abnormalities, but specialized tech-
niques are needed to detect many signiﬁcant cardiac
abnormalities. The heterozygote has a 50% reduction in the
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OPA1 transcript and protein in the mouse heart (Figure 1a).
Given the unique arrangement of mitochondria in cardiac
muscle, we examined whether OPA1 and mitochondrial fusion
play an important role in this tissue. Although no signiﬁcant
changes in the heart weight/tibia length ratio occurred at 3
months, heart weight and chamber size were mildly
decreased after 12 months in the OPA1 mutants (Figure 1b
and 1c). Cardiac function was assessed monthly by echocar-
diogram beginning at 3 months of age in OPA1+/ mice. No
signiﬁcant cardiac functional or gross structural abnormalities
were found in these mice until 12 months, when signiﬁcantly
impaired contraction developed. Fractional shortening (FS)
dropped from 74.18±1.81% to 47.87±2.75% (P<0.05) at 12
months in OPA1 mutants but did not change in WT hearts,
nor in OPA1 mutants at 3 months, as shown in Figure 1d
through 1f. There was no statistical difference in cardiac left
ventricular end diastolic dimension (LVEDD) between the
OPA1-mutant and WT groups (Figure 1g). Invasive hemo-
dynamic studies at 12 months showed abnormal pressure–
volume loops in OPA1+/ mice compared with WT littermates
(Figure 2a). The pressure–volume loops were mildly nar-
rowed, consistent with decreased cardiac output in the
OPA1+/ hearts. Most importantly, much less pressure was
generated by the OPA1+/ hearts with contraction (Fig-
ure 2a). LVDPmax was signiﬁcantly decreased in OPA1+/
hearts compared with WT (Figure 2b), whereas there was no
statistical difference in the left ventricular end diastolic
Figure 1. Cardiac OPA1 levels, gross cardiac morphology, and
cardiac dysfunction in the OPA1+/ mouse. a, OPA1 is reduced 50%
in the heterozygote heart. b, Heart weight/tibia length ratio indicates
the heart is slightly smaller in the mutants at 12 months (n=10 per
group). c, H & E staining of representative coronal sections of the
heart showing the 4 chambers from mutant and WT at 12 months.
Cardiac echo from 3 to 4 months (d) and 12 months (e) mice. f,
Decreased fractional shortening was evident at 12 months in the
OPA1 mutants (n=10 per group). g, Left ventricular end-diastolic
dimension (LVEDD, d) did not differ among groups, showing that no
ventricular dilatation was present despite decline in OPA1 hetero-
zygote heart function at 12 months (n=10 per group). WT indicates
wild-type; OPA, OPA1+/; 3 m, 3 to 4 months; 12 m, 12 months.
Data are represented as mean±SEM, and ANOVA was used to
calculate the statistical signiﬁcance.
Figure 2. OPA1 mutation associated with impaired hemodynamics
at 12 months. a, At 12 months, OPA1+/ mice had abnormal
pressure–volume loops compared with WT littermates. b, Left
ventricular developed pressure (LVDP) was decreased at 12 months
in the mutant hearts (n=10 to 12 per group). c, Cardiac output
was signiﬁcantly depressed at 12 months in the OPA1-mutant
heart (n=10 to 12 per group). d and e, Depressed response to beta
agonist – OPA1+/ hearts showed markedly less response to b
stimulus (isoproterenol), consistent with reduced cardiac inotropy
(n=6 per group). Data are represented as mean±SEM, and the t test
was used to calculate statistical signiﬁcance.
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pressure (LVEDP, Figure 2c). Cardiac output was markedly
reduced in OPA1 mutants, from 12.37±1.87 to 5.82±0.70
mL/min (P<0.001), compared with WT (Figure 2d). Cardiac
inotropic reserve was tested with the b-adrenergic agonist
isoproterenol using a standard protocol. The 12-month
OPA1+/ hearts showed little to no response to b-adrenergic
stimulus compared with WT (Figure 2e and 2f).
Calcium ﬂux is a critical component of contractility. In
isolated cardiomyocytes, 12-month OPA1 mutants had mark-
edly reduced amplitudes of both calcium transients and
contraction (Figure 3), and calcium transient decline and
myocyte relaxation exhibited slowed kinetics. These changes
recapitulate the cardiac dysfunction observed at the organ
level and demonstrate that dysfunction at the individual
myocyte level, rather than loss of myocytes per se, may be
critical in overall OPA1-mutant dysfunction.
Mitochondrial Structure and Function
Electron microscopy
EM was used to investigate cellular structure in the left
ventricle (Figure 4). The young WT heart showed orderly
Figure 3. Cell shortening and calcium transients. Representative
traces show depressed cell shortening (a) and calcium transients (b)
in old OPA1-mutant cardiomyocytes. Amplitude, time to peak, and
decay of cell shortening (c, e, and g) and calcium transients (d, f, and h)
all were consistent with decreased contractility of cardiomyocytes
from old OPA1 mutants. Data are represented as mean±SEM (n=9
to 10 per group). The t test was used to calculate statistical
signiﬁcance.
Figure 4. Electron microscopy of OPA1+/ and WT left ventricles
(a through d: 3 months; e through f: 12 months) demonstrating
mitochondria losing order and separating from each other at both 3
and 12 months, which is likely to be loss of mitochondrial fusion in
OPA1+/ hearts (b, d, f, h) compared with WTs (a, c, e, g). Higher-
magnitude images show mitochondria with loss of the normal
mitochondrial cristae structure (indicated by arrows) at 12 months in
OPA1 mutants (h) compared with WTs (g), suggested incomplete
mitochondrial respiratory function. WT indicates wild type; OPA,
OPA1+/; 3 m, 3 to 4 months; 12 m, 12 months.
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arrays of mitochondria between myoﬁlaments (Figure 4a and
4c). This pattern was not found in OPA1+/ hearts (Figure 4b
and 4d). The OPA1+/ hearts had greater disruption of
mitochondrial organization along with decreased density of
mitochondria/area, suggesting of loss of mitochondria (Fig-
ure 4c and 4d). Higher magniﬁcation (Figure 4g and 4h)
revealed damage to the normal mitochondrial cristae struc-
ture with loss of cristae, consistent with impaired mitochon-
drial respiratory function. The WT cardiac mitochondria
showed normal alignment along the sarcomere, but there
was some loss of cristae at 12 months (Figure 4e and 4g),
likely from aging.17
Mitochondrial function
Enzyme activities for complexes I, II, and IV were measured in
vitro in WT and OPA1+/ mouse hearts. Fresh cardiac
mitochondrial lysates were prepared and complex enzyme
activities measured using a 96-well plate–based assay
(Mitosciences, Eugene, OR). Activities of complexes I and IV
decreased signiﬁcantly in OPA1+/ hearts, whereas complex
II activity remained unchanged compared with WT (Figure 5a
through 5c). Direct mitochondrial respiration studies using
freshly isolated mitochondria from OPA1+/ and WT left
ventricles were done to complement the in vitro assays of
complex function. Depressed oxygen consumption was
detected both in succinate/ADP-driven state III respiration
and in FCCP-induced maximal respiration capacity in the 12-
month OPA1+/ cardiac mitochondria, whereas no difference
was found in the young (Figure 5d). Consistent with these
ﬁndings, basal cardiac ATP content in left ventricular tissue
lysate was signiﬁcantly decreased in the aged OPA1+/
compared with aged WT hearts (P<0.05). A more modest but
signiﬁcant decrease in ATP occurred in the aged WT (P<0.05;
Figure 5e). Complex I–driven ATP synthesis was measured in
freshly isolated cardiac mitochondria, and there was a
signiﬁcant decrease in ATP synthesis in aged OPA1+/
hearts, whereas no statistical differences were found in the
young groups (P<0.01; Figure 5f). These results suggest that
OPA1 plays a critical role in maintaining mitochondrial
respiration and sustaining mitochondrial energy production
at 12 months, which are known to be defective in heart
failure.
Mitochondrial DNA
Given the ultrastructural and functional evidence for mito-
chondrial dysfunction, we ﬁrst assessed mitochondrial-
encoded versus nuclear-encoded mitochondrial protein activ-
ity using traditional histochemical staining for cytochrome c
oxidase (COX, complex IV, brown stain) and succinate
dehydrogenase (SDH, complex II, blue stain). In both 3- and
12-month wild-type mice, the cardiac sections showed
predominantly brown COX staining of the cardiac ﬁbers
(Figure 6a, 1 and 3). However, in OPA1-mutant hearts, the
staining pattern in both groups was predominantly blue,
indicating reduced COX activity (Figure 6a, 2 and 4). This
characteristic abnormal blue histological pattern is often
found in cases of respiratory dysfunction due to mtDNA
defects,13,18 because SDH activity is encoded solely by the
nuclear genome, whereas COX activity is dependent on the
mitochondrial genome. The decreased COX staining is
consistent with the reduction of mitochondrial complex IV
enzyme activity in the OPA1-mutant hearts (Figure 5c).
Figure 5. Mitochondrial dysfunction in OPA1-mutant hearts. a
through c, Enzyme activities of complex I, II, and IV measured in WT
and OPA1+/ mouse hearts (n=6 to 7 per group). d, Oxygen
consumption rates (OCR) in WT and OPA1+/ heart mitochondria in
the presence of succinate. State III was induced by injection of ADP.
State IV was induced by inhibition of ATP synthase with oligomycin,
and uncoupled respiration rates were determined by injection of
mesoxalonitrile 4-triﬂuoromethoxyphenylhydrazone (FCCP). Anti-
mycin A (AA) was used to determine background, nonmitochondrial
OXPHOS, OCR (n=7 to 8 per group). e, Basal ATP content (n=4 per
group). f, Complex I–driven ATP synthesis measured in freshly
isolated cardiac mitochondria in the presence of the complex I
substrate pyruvate/malate, with and without rotenone. The ATP
measurements in the presence of rotenone were subtracted to give
ATP production via complex I. WT (n=4 per group) indicates wild type;
OPA, OPA1+/; 3 m, 3 to 4 months; 12 m, 12 to 14 months. Data are
represented as mean±SEM, and ANOVA was used to calculate
statistical signiﬁcance.
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Real-time PCR was employed to more precisely investigate
mtDNA copy number using the approach described by Sahin
et al.14 Despite the lack of grossly abnormal pathology or
function for the young OPA1 hearts, mtDNA copy number was
markedly reduced compared with WT littermates (Figure 6b).
The OPA1-mutant hearts had even greater reduction in
mtDNA copies per nuclear genome at 12 months (Figure 6b).
The mtDNA loss in this case is not likely related to
mitochondrial biogenesis because PGC-1a and TFAM protein
content was unchanged (Figure 7).
OPA1 Mutation and Oxidative Stress
Studies of ROS in OPA1-mutant cardiomyocytes showed
increased resting ROS compared with WT controls (Figure 8a
and 8b) at 12 months, indicating reduced ability to handle
ROS in OPA1-mutant hearts. A PCR array focused on
oxidative stress-related genes demonstrated a marked
reduction in the number of antioxidant genes, both at young
and older ages, in the OPA1-mutant heart (Table 1, the
entire list can be found as Table S1). Downregulated
antioxidant enzymes included Gpx3 and Gstk1. In the young
OPA1-mutant heart, the DNA repair-related gene Ercc6 and
the oxidative stress mediator protein Txnip were upregulat-
ed. These results suggest that OPA1 mutants may be more
vulnerable to ROS-inducing factors such as ischemia/
reperfusion. At 3 months, both OPA1-mutant and WT
myocytes showed low basal ROS levels. After 1 hour of
hypoxia and 1 hour of reoxygenation, both mutant and WT
young myocytes had increased ROS levels, but levels from
the mutant myocytes were strikingly increased compared
with WT myocytes (Figure 9). Moreover, by using a cell Live/
Dead assay (Invitrogen), it was found that 6 hours of hypoxia
and 1 hour of reoxygenation induced signiﬁcantly more cell
death in young OPA1-mutant cardiomyocytes compared with
WT myocytes (P<0.001, Figure 10), indicating greater vul-
nerability to ROS stress in the OPA1-mutant heart. In
addition, total antioxidant capacity was reduced signiﬁcantly
in both young and older OPA1-mutant hearts compared with
WT hearts (Figure 8c).
WT OPA1 +/-
3m
12m
a
1 2
3 4
b
0
500
1000
1500
2000
2500
3000
WT-3m OPA-3m WT-12m OPA-12m
m
tD
N
A:
nD
N
A
P = 0.02 P < 0.001
Figure 6. Loss of mtDNA stability in OPA1-mutant hearts. a,
Transverse sections of the left ventricle were stained for COX (brown)
and SDH (blue) activity. Blue staining indicates mitochondrial
dysfunction (reduction in COX) and mtDNA deletion. b, Quantitative
analysis of cardiac mtDNA copy number per nuclear genome at 3 and
12 months (n=4 to 5 per group). WT indicates wild type; OPA,
OPA1+/; 3 m, 3 to 4 months; 12 m, 12 to 14 months. Data are
represented as mean±SEM, and ANOVA was used to calculate
statistical signiﬁcance.
Figure 7. Expression of key proteins in OPA1+/ vs WT hearts at
12 months. Western blots showing unchanged TFAM, PGC1-a, MFN1,
MFN2, Bax, Bak, and Nrf2 in OPA1-mutant hearts. GAPDH was used
as a loading control.
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OPA1 Mutation and Apoptosis
Although OPA1-mediated mitochondrial fusion has been linked
to protection from apoptosis,19 there was no statistical
difference in TUNEL-positive cells or histological evidence of
cardiac myocyte loss in OPA1-mutant hearts (Figure 11). There
were no statistical differences found in mitochondrial intrinsic
apoptosis-related genes, including Bak1, Bcl2, Bcl2l1, and
Bnip3 (Table S2). In addition, no difference was detected in the
proapoptotic Bak and Bax proteins (Figure 7).
Discussion
Homozygous null mutations of OPA1 are embryonic lethal.9
The heterozygote had slow development of cardiomyopathy,
characterized by reduced fractional shortening, markedly
reduced inotropy, abnormal calcium transients, mitochondrial
dysfunction leading to reduced ATP levels, decreased anti-
oxidant gene expression, and increased ROS. However,
despite these many changes, we detected no increase in
apoptosis. mtDNA copy number was strikingly reduced, and
this certainly contributed to some of the abnormalities,
including complex IV dysfunction through reduction of COX
expression. Interestingly, the onset of eye disease9 and
cardiomyopathy occurred simultaneously at 12 months. These
ﬁnding suggest a progressive pathological process induced by
OPA1 reduction. Although there are some changes with aging
in the WT, leading to mild reduction in ATP content and
mitochondrial ultrastructure, the OPA1 mutant has far more
dramatic effects on mitochondrial morphology and function.
Recently, Dorn et al reported that silencing of OPA1 and
mitochondrial assembly regulatory factor (MARF) induces
heart tube dilation in a Drosophila model.20 In another report,
a different OPA1 splicing mutation, which leads to an in-frame
deletion of 27 amino acid residues in the GTPase domain,
showed no evidence of cardiac dysfunction at 6 months but
surprisingly demonstrated more severe hypertrophy after
chronic pressure overload.21 Furthermore, it has been
reported that MFN2-deﬁcient mice display modest cardiac
hypertrophy accompanied by slight functional deterioration.22
Reduction in either MFN1 or MFN2 can be partially compen-
sated for by the other MFN protein, suggesting some overlap
in function.23 Knockout of either MFN1 or MFN2 was
protective against ischemia/reperfusion injury in cardiomyo-
cytes,22,24 whereas a combination knockout of MFN1/2 led
to rapidly lethal cardiac failure.25 The mitochondrial ﬁssion
protein Drp1 has been linked to dilated cardiomyopathy.26
OPA1 is the only protein known to mediate inner mitochon-
drial membrane fusion. Our previous work demonstrated a
signiﬁcant decrease of OPA1 protein content in both human
and rat heart failure, whereas MFN1/2 surprisingly increased
in human heart failure.8 In the current study, OPA1 mutation
led to cardiomyopathy without changing the gene and protein
level of MFN1/2 (Table S2 and Figure 7). These results
suggest a unique role of OPA1 in regulating mitochondrial
fusion, and depressed mitochondrial fusion may play a critical
role in the downward progression of cardiomyopathies.
Decreased ATP production in OPA1-mutant hearts is likely a
major factor in the decreased function, as demonstrated by
echocardiograhy and hemodynamics. Depressed cardiomyocyte
Table 1. Summary of Transcriptional Regulation of Oxidative Stress–Related Genes
Gene Description Function Fold Induction P
WT vs OPA1+/ (3 to 4 months)
Ercc6 Excision repair cross-complementing rodent repair deﬁciency,
complementation group 6
DNA repair 1.88 0.044
Txnip Thioredoxin interacting protein Oxidative stress mediator 2.29 0.028
Gpx2 Glutathione peroxidase 2 Antioxidants 3.34 0.014
Gpx3 Glutathione peroxidase 3 Antioxidants 3.10 0.038
Gstk1 Glutathione S-transferase kappa 1 Antioxidants 2.16 0.038
Txnrd2 Thioredoxin reductase 2 Antioxidants 5.01 0.047
WT vs OPA1+/ (12 months)
Cyba Cytochrome b-245, alpha polypeptide Antioxidants 1.31 0.028
Gpx3 Glutathione peroxidase 3 Antioxidants 2.67 0.007
Gstk1 Glutathione S-transferase kappa 1 Antioxidants 1.63 0.024
Prdx6-rs1 Peroxiredoxin 6, related sequence 1 Antioxidants 3.41 0.021
Srxn1 Sulﬁredoxin 1 homolog (Saccharomyces cerevisiae) Antioxidants 2.63 0.039
Positive value indicates upregulation; negative value, downregulation; WT, wild type; and OPA1, optic atrophy 1.
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contractility and calcium transients may also partly result
from the depressed ATP levels. To further understand the
mechanism linking OPA1 to ATP generation, we measured
mitochondrial oxygen consumption in the OPA1-mutant
hearts. OCR decreased signiﬁcantly in the OPA1-mutant
cardiac mitochondria at 12 months. This is not surprising, as
there are reports demonstrating a direct correlation between
mitochondrial fusion and oxidative phosphorylation capac-
ity.27 Inhibition of mitofusins-mediated mitochondrial fusion in
skeletal muscle,13 ﬁbroblasts,28 and MEFs23 results in
reduced oxygen consumption. The depressed OCR suggested
electron transport chain (ETC) dysfunction, and this was
conﬁrmed by in vitro enzyme activity assays demonstrating
that complex I and complex IV had decreased activity,
whereas complex II activity was normal. This result is
consistent with our ﬁnding of decreased COX activity
(complex IV) by staining.
Although the pancreas-speciﬁc knockout of OPA1 does not
affect mtDNA copy number,29 our results demonstrate
convincing loss of mtDNA copies in both young and older
OPA1-mutant hearts. There is one theory that mitochondrial
fusion/ﬁssion serves as a means of distribution of mtDNA to
the progeny of mammalian cells,30 which is supported by
experiments demonstrating that the loss of mitofusins leads
to loss of mtDNA in muscle.13 Recently, Elachouri et al found
that silencing of OPA1 leads to mtDNA depletion, secondary
to inhibition of mtDNA replication.31 In a series of clinical
studies, speciﬁc OPA1 mutations were observed to induce the
accumulation of mtDNA deletions in the skeletal muscle of
patients.32,33 Altogether these observations suggested that
altering mitochondrial dynamics affects the maintenance of
mtDNA integrity. The loss of mtDNA induced by OPA1
Figure 8. Reactive oxygen species (ROS) accumulated in OPA1-
mutant hearts. a, Confocal microscopy image showing ROS
accumulated in 12-month OPA1-mutant cardiomyocytes (n=4 donors
per group). ROS was detected by a ﬂuorogenic probe, CellROX Deep
Red reagent. Nuclei stained with DAPI. Bar=100 lm. b, Summary of
ROS intensity data from multiple experiments. c, Total antioxidant
capacity measured in WT and OPA1-mutant left ventricles (n=5 per
group). WT indicates wild type; OPA, OPA1+/; 3 m, 3 to 4 months;
12 m, 12 to 14 months. Data are represented as mean±SEM, and the
t test was used to calculate statistical signiﬁcance.
Figure 9. Reactive oxygen species (ROS) measured in young OPA1-
mutant cardiomyocytes. a, ROS are undetectable in either WT or
OPA1+/ cardiomyocytes in the basal state. b, ROS after 1 hour of
simulated ischemia with 1 hour of reoxygenation. c, Summary of ROS
intensity data from multiple experiments. ROS were detected by a
ﬂuorogenic probe, CellROX Deep Red reagent (n=4 donors per
group). Nuclei were stained with DAPI. Bar=100 lm. WT indicates
wild type; OPA, OPA1+/; 3 m: 3 to 4 months; I/R, ischemia/
reoxygenation. Data are represented as mean±SEM, and ANOVA was
used to calculate statistical signiﬁcance.
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mutation may be the key factor in the development of cardiac
mitochondrial dysfunction.
The mitochondrial fusion proteins OPA1 and MFN1/2 have
been shown to protect cells from apoptosis. Increased ﬁssion,
decreased fusion, or both can induce caspase activation, Bax
translocation to mitochondria, and cytochrome c release.19
Bak may also regulate apoptosis by interacting with the
mitofusins.34 Interestingly, Bax may also positively regulate
mitochondrial fusion exclusively through homotypic MFN2
trans complexes.35 However, most of these results were
generated in cultured cells. Even though our data from a
myocytelike cell line indicates reduction of OPA1 induces
apoptosis,8 we did not detect an increase in TUNEL-positive
apoptotic myocytes in mouse left ventricular sections.
Furthermore, we did not ﬁnd changes in Bax or Bak
expression in OPA1-mutant hearts. Thus, the mechanism of
decreased cardiac function in the OPA1 mutant is not an
increase in apoptosis. A similar conclusion was reached in an
in vivo study in the pancreas,29 where no increase in
apoptosis associated with pancreas-speciﬁc knockout of
OPA1.
OPA1 mutation–related cardiomyopathy was associated
with increased ROS generation. Decreased mitochondrial ETC
complex activity and mtDNA depletion may have contributed
to this ROS accumulation. The accumulated ROS could also
damage the ETC and mtDNA, creating a vicious cycle of
damage. We were surprised to ﬁnd marked depression of
expression of a number of nuclear-encoded antioxidant genes,
which would further exacerbate the ROS damage. The protein
content of Nrf2, a transcription factor inducing expression of
several antioxidant enzymes, was unchanged in OPA1-mutant
hearts (Figure 7). The link between reduced OPA1 and
reduced nuclear transcription will need to be addressed in
future studies. Although there is no marked cardiac dysfunc-
tion evident in OPA1 mutants at 3 to 4 months, the decreased
mtDNA copy number and increased ROS accumulation in
these functionally “normal” hearts are evidence of signiﬁcant
abnormality despite normal function.
Mitochondrial morphologic abnormalities are associated
with different types of cardiomyopathy8,36 in which OPA1 may
be involved. Further work will be needed to fully deﬁne the
role of abnormal mitochondrial ﬁssion/fusion in heart failure.
The contribution of unbalanced mitochondrial fusion/ﬁssion
to heart failure as a cause of myocardial injury remains to be
proven. Nevertheless, the restoration of mitochondrial fusion/
ﬁssion symmetry may help to rescue the failing heart.
Treatment of adult murine cardiac myocytes with mitochon-
drial division inhibitor-1, a pharmacological inhibitor of Drp1,
reduced cell death and infarct size after ischemia/reperfusion
injury.37 No cardiac disorders have been described in patients
with OPA1 or similar mutations involving the ﬁssion/fusion
genes as seen in inherited maladies like Charcot–Marie–Tooth
disease. Our results indicate that, at least for OPA1, cardiac
abnormalities are not completely manifest until the develop-
ment of blindness. Although the OPA1-mutant mice survived
more than 1 year and appeared healthy, we cannot exclude
the changes in other organs had an effect on cardiac function,
though this is unlikely. Thus, in patients with these diseases,
reduced cardiac function may go undetected secondary to
Figure 10. Cardiomyocyte viability after simulated ischemia fol-
lowed by reoxygenation. Decreased OPA+/-cardiomyocyte viability
after 6 hours of simulated ischemia and 1 hour of reoxygenation
measured by a Live⁄Dead Viability Kit, in which green-ﬂuorescent
calcein-AM indicates live cells and red-ﬂuorescent ethidium homod-
imer-1 indicates dead cells with loss of plasma membrane integrity.
Percentage of live cardiomyocytes was calculated (n=4 donors per
group). WT indicates wild type; OPA, OPA1+/; 3 m, 3 to 4 months; I/
R, ischemia/reoxygenation. Data are represented as mean±SEM, and
ANOVA was used to calculate statistical signiﬁcance.
Figure 11. Apoptosis at 12 months. a, Representative confocal
images of TUNEL-positive cells in left ventricle sections by TUNEL.
Green ﬂuorescence indicates TUNEL-positive apoptotic nuclei, with
DAPI as a nuclear counter stain. b, Percentage of apoptotic
cardiomyocytes was calculated based on TUNEL-positive ﬂuores-
cence of cardiac myocytes/total cardiac myocytes (n=3 donors per
group). Data are represented as mean±SEM, and the t test was used
to calculate statistical signiﬁcance.
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reduced physical activity secondary to loss of vision. It would
be expected that patients with such mutations would have
impaired cardiac reserve with reduced ability to respond to
high-stress disease states such as myocardial infarction and
sepsis. The OPA1-mutant mice have reduced cardiac reserve,
as shown by the lack of response to isoproterenol or to
ischemia/reperfusion injury, as shown in the current study,
suggesting that patients with OPA1 and related inherited
mitochondrial diseases should be screened for abnormalities
of cardiac function.
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Fold 
induction P value q value
Fold 
induction P value q value
Gpx8 Glutathione peroxidase 8 (putative) -1.43 0.36 0.37 1.03 0.84 0.37
Aass Aminoadipate-semialdehyde synthase 1.16 0.61 0.41 2.23 0.50 0.35
Als2 Amyotrophic lateral sclerosis 2 (juvenile) homolog (human) -1.38 0.41 0.37 -1.79 0.20 0.35
Apc Adenomatosis polyposis coli 1.89 0.10 0.34 1.41 0.57 0.35
Apoe Apolipoprotein E -1.29 0.65 0.41 -1.27 0.56 0.35
Aqr Aquarius -1.26 0.48 0.38 -1.36 0.12 0.35
Atr Ataxia telangiectasia and rad3 related 1.19 0.95 0.52 -1.42 0.38 0.35
Cat Catalase 1.33 0.27 0.34 -1.29 0.47 0.35
Ccs Copper chaperone for superoxide dismutase 1.08 0.63 0.41 -1.23 0.56 0.35
Xirp1 Xin actin-binding repeat containing 1 -1.84 0.47 0.38 -2.10 0.11 0.35
Ctsb Cathepsin B 1.44 0.34 0.36 1.54 0.56 0.35
Cyba Cytochrome b-245, alpha polypeptide -1.53 0.40 0.37 -1.31 0.03 0.26
Cygb Cytoglobin -1.58 0.46 0.38 -1.14 0.76 0.35
Dnm2 Dynamin 2 1.76 0.27 0.34 -1.23 0.56 0.35
Duox1 Dual oxidase 1 -1.72 0.72 0.44 -1.70 0.37 0.35
Ehd2 EH-domain containing 2 -2.05 0.26 0.34 -2.47 0.22 0.35
Epx Eosinophil peroxidase -1.35 0.43 0.37 -1.65 0.46 0.35
Ercc2 Excision repair cross-complementing rodent repair deficiency, complementation group 2 -1.34 0.75 0.45 -2.19 0.32 0.35
Ercc6 Excision repair cross-complementing rodent repair deficiency, complementation group 6 1.88 0.04 0.34 1.74 0.30 0.35
Fancc Fanconi anemia, complementation group C -1.16 0.49 0.38 -1.14 0.73 0.35
Fmo2 Flavin containing monooxygenase 2 -2.37 0.09 0.34 -1.60 0.25 0.35
Gab1 Growth factor receptor bound protein 2-associated protein 1 -1.82 0.25 0.34 -1.93 0.49 0.35
Gpx1 Glutathione peroxidase 1 1.28 0.99 0.52 1.16 0.75 0.35
Gpx2 Glutathione peroxidase 2 -3.34 0.01 0.34 -1.38 0.51 0.35
Gpx3 Glutathione peroxidase 3 -3.10 0.04 0.34 -2.67 0.01 0.25
Gpx4 Glutathione peroxidase 4 -1.81 0.15 0.34 -1.47 0.28 0.35
Gpx5 Glutathione peroxidase 5 -1.37 0.31 0.34 1.35 0.70 0.35
Gpx6 Glutathione peroxidase 6 -1.49 0.26 0.34 -1.02 0.66 0.35
Gpx7 Glutathione peroxidase 7 -1.40 0.27 0.34 -1.85 0.51 0.35
Gsr Glutathione reductase -2.05 0.11 0.34 -1.64 0.50 0.35
Gstk1 Glutathione S-transferase kappa 1 -2.16 0.04 0.34 -1.63 0.02 0.26
Hbq1 Hemoglobin, theta 1 1.05 0.85 0.48 1.22 0.93 0.39
Idh1 Isocitrate dehydrogenase 1 (NADP+), soluble -1.80 0.08 0.34 -1.99 0.34 0.35
Ift172 Intraflagellar transport 172 homolog (Chlamydomonas) -1.23 0.25 0.34 -1.68 0.35 0.35
Il19 Interleukin 19 -2.67 0.22 0.34 -1.36 0.71 0.35
Il22 Interleukin 22 1.13 0.77 0.45 -1.12 0.72 0.35
Kif9 Kinesin family member 9 1.41 0.54 0.39 -1.09 0.66 0.35
Lpo Lactoperoxidase -1.75 0.16 0.34 -1.20 0.59 0.35
Mb Myoglobin 1.31 0.62 0.41 1.50 0.27 0.35
Mpo Myeloperoxidase -4.67 0.42 0.37 1.84 0.87 0.37
Mpp4 Membrane protein, palmitoylated 4 (MAGUK p55 subfamily member 4) -1.37 0.31 0.34 1.35 0.70 0.35
Ncf2 Neutrophil cytosolic factor 2 1.09 0.92 0.51 -1.26 0.32 0.35
Ngb Neuroglobin -1.78 0.15 0.34 1.35 0.70 0.35
Nos2 Nitric oxide synthase 2, inducible 1.60 0.81 0.46 2.40 0.41 0.35
Nox1 NADPH oxidase 1 -2.36 0.06 0.34 -1.78 0.36 0.35
Nox4 NADPH oxidase 4 -2.53 0.13 0.34 -1.08 0.79 0.36
Noxa1 NADPH oxidase activator 1 -1.49 0.27 0.34 1.25 0.69 0.35
Noxo1 NADPH oxidase organizer 1 1.13 0.68 0.43 -1.45 0.58 0.35
Table S1: Transcriptional regulation of genes related to Oxidative Stress and Antioxidant Defense
RT² Profiler™ PCR Array Mouse Oxidative Stress and Antioxidant Defense ( PAMM-065A )
Gene Description
OPA1 +/- vs. WT (12 months)OPA1 +/- vs. WT (3-4 months)
Nqo1 NAD(P)H dehydrogenase, quinone 1 1.24 0.48 0.38 1.16 0.98 0.40
Nudt15 Nudix (nucleoside diphosphate linked moiety X)-type motif 15 -2.48 0.11 0.34 -1.60 0.51 0.35
Nxn Nucleoredoxin 1.45 0.61 0.41 1.36 0.64 0.35
Park7 Parkinson disease (autosomal recessive, early onset) 7 -1.41 0.28 0.34 -2.45 0.13 0.35
Ppp1r15b Protein phosphatase 1, regulatory (inhibitor) subunit 15b -1.19 0.56 0.39 -1.16 0.52 0.35
Prdx1 Peroxiredoxin 1 1.41 0.27 0.34 1.12 0.64 0.35
Prdx2 Peroxiredoxin 2 -1.21 0.56 0.39 -2.33 0.05 0.33
Prdx3 Peroxiredoxin 3 1.24 0.81 0.46 1.07 0.74 0.35
Prdx4 Peroxiredoxin 4 1.22 0.99 0.52 1.46 0.47 0.35
Prdx5 Peroxiredoxin 5 -3.57 0.11 0.34 -2.53 0.11 0.35
Prdx6 Peroxiredoxin 6 -1.96 0.18 0.34 -1.64 0.18 0.35
Prdx6-rs1 Peroxiredoxin 6, related sequence 1 -4.21 0.25 0.34 -3.41 0.02 0.26
Prnp Prion protein -1.83 0.30 0.34 -2.52 0.21 0.35
Psmb5 Proteasome (prosome, macropain) subunit, beta type 5 -1.15 0.56 0.39 -1.46 0.30 0.35
Ptgs1 Prostaglandin-endoperoxide synthase 1 -1.89 0.12 0.34 -1.27 0.35 0.35
Ptgs2 Prostaglandin-endoperoxide synthase 2 -2.34 0.37 0.37 -1.15 0.65 0.35
Rag2 Recombination activating gene 2 -1.84 0.13 0.34 -1.49 0.59 0.35
Recql4 RecQ protein-like 4 1.14 0.49 0.38 1.46 0.73 0.35
Scd1 Stearoyl-Coenzyme A desaturase 1 -1.60 0.42 0.37 -1.55 0.22 0.35
Serpinb1b Serine (or cysteine) peptidase inhibitor, clade B, member 1b -1.33 0.49 0.38 1.70 0.26 0.35
Slc38a1 Solute carrier family 38, member 1 -1.17 0.56 0.39 2.14 0.31 0.35
Slc41a3 Solute carrier family 41, member 3 1.60 0.41 0.37 -1.24 0.47 0.35
Sod1 Superoxide dismutase 1, soluble 11.38 0.74 0.45 -1.61 0.39 0.35
Sod2 Superoxide dismutase 2, mitochondrial 2.68 0.40 0.37 1.04 0.69 0.35
Sod3 Superoxide dismutase 3, extracellular -1.81 0.32 0.34 -1.91 0.12 0.35
Srxn1 Sulfiredoxin 1 homolog (S. cerevisiae) -1.95 0.22 0.34 -2.63 0.04 0.29
Tmod1 Tropomodulin 1 -2.02 0.19 0.34 -1.57 0.45 0.35
Tpo Thyroid peroxidase -2.79 0.13 0.34 -2.24 0.39 0.35
Txnip Thioredoxin interacting protein 2.29 0.03 0.34 1.04 0.86 0.37
Txnrd1 Thioredoxin reductase 1 -1.97 0.99 0.52 -1.36 0.47 0.35
Txnrd2 Thioredoxin reductase 2 -5.01 0.05 0.34 -1.41 0.47 0.35
Txnrd3 Thioredoxin reductase 3 -8.71 0.65 0.41 1.09 0.87 0.37
Ucp3 Uncoupling protein 3 (mitochondrial, proton carrier) 2.40 0.11 0.34 -1.14 0.58 0.35
Vim Vimentin -1.06 0.77 0.45 1.72 0.42 0.35
Xpa Xeroderma pigmentosum, complementation group A 6.14 0.95 0.52 1.12 0.84 0.37
Zmynd17 Zinc finger, MYND domain containing 17 -1.16 0.52 0.39 1.05 0.99 0.40
Positvie value = up-regulation; negtive value = down-regulation.
Gene Description Fold induction P value q value
Aifm2 Apoptosis-inducing factor, mitochondrion-associated 2 1.08 0.92 0.80
Aip Aryl-hydrocarbon receptor-interacting protein 1.40 0.15 0.59
Bak1 BCL2-antagonist/killer 1 1.55 0.39 0.59
Bbc3 BCL2 binding component 3 2.70 0.38 0.59
Bcl2 B-cell leukemia/lymphoma 2 1.89 0.44 0.59
Bcl2l1 Bcl2-like 1 -2.81 0.15 0.59
Bid BH3 interacting domain death agonist 1.52 0.52 0.61
Bnip3 BCL2/adenovirus E1B interacting protein 3 -1.63 0.16 0.59
Cdkn2a Cyclin-dependent kinase inhibitor 2A 1.87 0.43 0.59
Cox10 COX10 homolog, cytochrome c oxidase assembly protein, heme A: farnesyltransferase (yeast) -1.56 0.97 0.81
Cox18 COX18 cytochrome c oxidase assembly homolog (S. cerevisiae) 1.20 0.47 0.59
Cpt1b Carnitine palmitoyltransferase 1b, muscle -1.03 0.71 0.73
Cpt2 Carnitine palmitoyltransferase 2 1.28 0.56 0.63
Dnajc19 DnaJ (Hsp40) homolog, subfamily C, member 19 -1.25 0.91 0.80
Dnm1l Dynamin 1-like 1.31 0.40 0.59
Fis1 Fission 1 (mitochondrial outer membrane) homolog (yeast) 1.08 0.65 0.69
Fxc1 Fractured callus expressed transcript 1 -1.29 0.75 0.74
Grpel1 GrpE-like 1, mitochondrial 1.30 0.27 0.59
Hsp90aa1 Heat shock protein 90, alpha (cytosolic), class A member 1 1.29 0.29 0.59
Hspd1 Heat shock protein 1 (chaperonin) 1.42 0.33 0.59
Immp1l IMP1 inner mitochondrial membrane peptidase-like (S. cerevisiae) 1.32 0.35 0.59
Immp2l IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae) 1.83 0.25 0.59
Lrpprc Leucine-rich PPR-motif containing -1.05 0.94 0.80
Mfn1 Mitofusin 1 1.49 0.44 0.59
Mfn2 Mitofusin 2 1.20 0.54 0.62
Mipep Mitochondrial intermediate peptidase 1.13 0.54 0.62
Msto1 Misato homolog 1 (Drosophila) -1.17 0.90 0.80
Mtx2 Metaxin 2 1.05 0.67 0.70
Nefl Neurofilament, light polypeptide 1.54 0.44 0.59
Opa1 Optic atrophy 1 homolog (human) -2.23 0.01 0.59
Pmaip1 Phorbol-12-myristate-13-acetate-induced protein 1 2.17 0.47 0.59
Rhot1 Ras homolog gene family, member T1 1.85 0.37 0.59
Rhot2 Ras homolog gene family, member T2 -1.05 0.84 0.79
Sfn Stratifin 2.74 0.45 0.59
Sh3glb1 SH3-domain GRB2-like B1 (endophilin) 1.42 0.44 0.59
Slc25a1 Solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1 1.75 0.31 0.59
Slc25a10 Solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), member 10 2.43 0.22 0.59
Slc25a12 Solute carrier family 25 (mitochondrial carrier, Aralar), member 12 -1.77 0.34 0.59
Slc25a13 Solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 13 1.63 0.24 0.59
Slc25a14 Solute carrier family 25 (mitochondrial carrier, brain), member 14 1.46 0.37 0.59
Slc25a15 Solute carrier family 25 (mitochondrial carrier ornithine transporter), member 15 1.63 0.38 0.59
Slc25a16 Solute carrier family 25 (mitochondrial carrier, Graves disease autoantigen), member 16 1.82 0.11 0.59
Slc25a17 Solute carrier family 25 (mitochondrial carrier, peroxisomal membrane protein), member 17 1.30 0.39 0.59
Slc25a19 Solute carrier family 25 (mitochondrial thiamine pyrophosphate carrier), member 19 1.51 0.27 0.59
Table S2: Transcriptional regulation of key genes related mitochondria (12 months)
Slc25a2 Solute carrier family 25 (mitochondrial carrier, ornithine transporter) member 2 2.73 0.33 0.59
Slc25a20 Solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20 -1.03 0.84 0.79
Slc25a21 Solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21 5.01 0.41 0.59
Slc25a22 Solute carrier family 25 (mitochondrial carrier, glutamate), member 22 1.25 0.38 0.59
Slc25a23 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 1.02 0.89 0.80
Slc25a24 Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 24 1.88 0.41 0.59
Slc25a25 Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25 3.13 0.24 0.59
Slc25a27 Solute carrier family 25, member 27 1.43 0.38 0.59
Slc25a3 Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 -1.12 0.34 0.59
Slc25a30 Solute carrier family 25, member 30 1.73 0.43 0.59
Slc25a31 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 3.42 0.43 0.59
Slc25a37 Solute carrier family 25, member 37 1.25 0.48 0.60
Slc25a4 Solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 1.40 0.27 0.59
Slc25a5 Solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 1.14 0.25 0.59
Sod1 Superoxide dismutase 1, soluble -1.51 0.58 0.64
Sod2 Superoxide dismutase 2, mitochondrial -1.11 0.84 0.79
Stard3 START domain containing 3 -1.27 0.93 0.80
Taz Tafazzin 1.55 0.20 0.59
Timm10 Translocase of inner mitochondrial membrane 10 homolog (yeast) -1.59 0.52 0.61
Timm17a Translocase of inner mitochondrial membrane 17a 1.44 0.29 0.59
Timm17b Translocase of inner mitochondrial membrane 17b 1.39 0.39 0.59
Timm22 Translocase of inner mitochondrial membrane 22 homolog (yeast) 1.24 0.12 0.59
Timm23 Translocase of inner mitochondrial membrane 23 homolog (yeast) -1.22 0.63 0.69
Timm44 Translocase of inner mitochondrial membrane 44 1.39 0.16 0.59
Timm50 Translocase of inner mitochondrial membrane 50 homolog (yeast) -1.03 0.72 0.73
Timm8a1 Translocase of inner mitochondrial membrane 8 homolog a1 (yeast) 1.00 0.84 0.79
Timm8b Translocase of inner mitochondrial membrane 8 homolog b (yeast) -1.06 0.92 0.80
Timm9 Translocase of inner mitochondrial membrane 9 homolog (yeast) 1.50 0.36 0.59
Tomm20 Translocase of outer mitochondrial membrane 20 homolog (yeast) -1.10 0.92 0.80
Tomm22 Translocase of outer mitochondrial membrane 22 homolog (yeast) 1.26 0.45 0.59
Tomm34 Translocase of outer mitochondrial membrane 34 1.44 0.07 0.59
Tomm40 Translocase of outer mitochondrial membrane 40 homolog (yeast) 2.94 0.36 0.59
Tomm40l Translocase of outer mitochondrial membrane 40 homolog-like (yeast) 1.18 0.49 0.60
Tomm70a Translocase of outer mitochondrial membrane 70 homolog A (yeast) 1.56 0.19 0.59
Trp53 Transformation related protein 53 1.59 0.40 0.59
Tspo Translocator protein 1.56 0.33 0.59
Ucp1 Uncoupling protein 1 (mitochondrial, proton carrier) 5.89 0.47 0.59
Ucp2 Uncoupling protein 2 (mitochondrial, proton carrier) -1.30 0.99 0.82
Ucp3 Uncoupling protein 3 (mitochondrial, proton carrier) -1.12 0.64 0.69
Uxt Ubiquitously expressed transcript 1.24 0.36 0.59
Positvie value = up-regulation; negtive value = down-regulation.
Table S3: Primers used to identify mtDNA copy number. 
 
Mitochondrial primers 
COXIF 
COXIR 
CytBF 
CytBR 
CTGAGCGGGAATAGTGGGTA 
TGGGGCTCCGATTATTAGTG 
ATTCCTTCATGTCGGACGAG 
ACTGAGAAGCCCCCTCAAAT 
Genomic primers 
H19R 
H19F 
B1globinF 
B1globinR 
GTCCACGAGACCAATGACTG 
GTACCCACCTGTCGTCC 
GCACCTGACTGATGCTGAGAA 
TTCATCGGCGTTCACCTTTCC  
 
